StemCells ! Günstig wie nie ....

The first patient transplanted in the trial, a 23-year-old German man, suffered a spinal cord injury in an automobile accident in April of this year. He sustained a complete loss of sensation and mobility from the waist down. When asked about his decision to enroll in this leading-edge study, he said: "This terrible injury crossed out almost all my life plans, and has led me to an unexpected path. Participating in this clinical trial not only gives me a sense of hope, but it also helps move this important research forward."

"With this first patient enrolled and dosed, we remain on track to meet our goal of treating the first cohort of patients by the end of this year," said Stephen Huhn MD, FACS, FAAP, Vice President and Head of the CNS Program at StemCells, Inc. "While the trial's first cohort will consist of patients with the most severe, complete injury, the second and third cohorts will progress to patients with less severe, incomplete injury. This unique trial design will allow us to evaluate the potential of our HuCNS-SC cells as a treatment for a broad spectrum of spinal cord injury patients. Even a small improvement could have a marked impact on quality of life for the millions of people who suffer from this debilitating condition."

About the Clinical Trial

The Phase I/II clinical trial of StemCells, Inc.'s HuCNS-SC purified human adult neural stem cells is designed to assess both safety and preliminary efficacy. Twelve patients with thoracic (chest-level) neurological injuries at the T2-T11 level are planned for enrollment. The first three patients will all have injuries classified as ASIA A, in which there is no apparent neurological function below the injury level, the most severe level identified by the American Spinal Injury Association (ASIA) Impairment Scale. The second and third cohorts will be patients classified as ASIA B and ASIA C, those with less severe injury, in which there is some preservation of sensory or motor function. In addition to assessing safety, the trial will assess preliminary efficacy based on defined clinical endpoints, such as changes in sensation, motor and bowel/bladder function.

All patients will receive HuCNS-SC cells through direct transplantation into the spinal cord and will be temporarily immunosuppressed. Patients will be evaluated regularly in the post-transplant period in order to monitor and assess the safety of the HuCNS-SC cells, the surgery and the immunosuppression, as well as to measure any recovery of neurological function below the injury site. The Company intends to follow the effects of this therapy long-term, and a separate 4-year observational study will be initiated at the conclusion of this trial.

For information on patient enrollment, interested parties may contact the study nurse either by phone at +41 44 386 39 01, or by email at stemcells.pz@balgrist.ch.

Additional information about the Company's spinal cord injury program can be found on the StemCells, Inc. website at www.stemcellsinc.com/Therapeutic-Programs/Clinical-Trials.htm and at www.stemcellsinc.com/Therapeutic-Programs/...-Cord-Injury.htm, including video interviews with Company executives and independent collaborators.

About Chronic Spinal Cord Injury

According to a study reported by the Christopher and Dana Reeve Foundation, nearly 1.3 million people in the United States are estimated to be living with chronic spinal cord injury. The chronic phase of spinal cord injury is considered to begin when inflammation has stabilized and recovery has reached a plateau, which is typically several months following injury. Currently, there are no effective treatment options for patients with chronic spinal cord injury, and treatment approaches have generally targeted the acute and sub-acute time points, which are within hours or days of injury. Given the unmet need in chronic spinal cord injury, restoring some degree of function for patients at time points beyond the acute phase could have a transformative impact on the field. StemCells hopes to address a broad population of spinal cord-injured patients by opening the window of opportunity for therapeutic intervention well after the acute injury and targeting a wide range of injury levels and degrees of impairment.

MFG
Chali

gab schon lange keine news mehr...

schon mal nicht schlecht angesichts der letzten Umsätze.

Dazu wird seit einigen Tagen an der 90 geknabbert,
noch ist es nicht so weit.
Nächste Woche wird die 90 geknackt, dann geht es fix weiter.
isr hat es heute vorgemacht, STEM macht es auch noch nach.

wie schön,dass du meinen alten Thread mal wiederbelebt hast ! Hast du dir wirklich 100K zugelegt ? Gratulation !! Seit dem Geron raus ist aus der Geschichte,könnte STEM noch massig steigen,siehe heute ......

MFG
Chali

BOSTON (MarketWatch) -- Shares of StemCells Inc. /quotes/zigman/5728491/quotes/nls/stem STEM +51.74% rocketed nearly 40% to $1.19 on Tuesday on news that a study of its neural stem-cell therapy restored memory and enhanced synaptic function in laboratory animals with Alzheimer's disease. The study noted that the improvements were seen without a reduction of two proteins associated with the disease, beta amyloid and tau, which have been the focus of most ongoing Alzheimer's research. The stem cells were transplanted in an area of the brain called the hippocampus, which is believed to control memory. "While reducing beta amyloid and tau burden is a major focus in AD research, our data is intriguing because we obtained improved memory without a reduction in either of these pathologies," said StemCells Stephen Huhn, in a statement. "AD is a complex and challenging disorder. The field would benefit from the pursuit of a diverse range of treatment approaches and our neural stem cells now appear to offer a unique and viable contribution in the battle against this devastating disease," Huhn added.

MFG
Chali

8:31AM StemCells announces its human neural stem cells restore memory in models of Alzheimer's Disease (STEM) 0.87 : The study results showed that transplanting the cells into a specific region of the brain, the hippocampus, statistically increased memory in two different animal models. Importantly, these results did not require reduction in beta amyloid or tau that accumulate in the brains of patients with AD and account for the pathological hallmarks of the disease.

MFG
Chali

hatte nur immer mal den Umsatz beobachtet,
und da war dieser 100 k Kauf schon herausragend
bei dem eingeschlafenen vol. (war aber nicht meiner, hallo 100 k?)
nun heute ist ja ordentlich vol drin.
Habe natürlich meine 10 K zu früh verkauft,
ich lerne es halt nicht, mal wenigstens ein paar freebies laufen zu lassen.
Aber ich hätte wetten können, dass die noch mal ein gap-close versuchen
und hatte mich knapp über nem Dollar wieder positioniert,
aber ne, sonst machen sie jedes gap-up zu,
heute natürlich nicht, is klar.




nun janettes

die amis sind so geil, erst intressiert es keine sau und schicken das ding
auf 58 und nun übertreiben sie das teil nach oben
wegen einer pre-clinical-news.
Ich hab ja grundsätzlich nichts dagegen, aber das sie diesmal das gap-up nicht mal annähernd kurz
intraday versucht haben zu schließen, nehm ich ihnen schon übel, Idioten, grrr.
Was solls, bin ich selbst schuld, dass ich nicht paar hab weiter laufen lassen.
Viel Erfolg den Neu- und Altinvestierten.

staender....ggg
aber das gap werdens wohl erst noch zu machen

dollar

aber bei den Amis weiß man nie! Oxigene ist auch mal tagelang gestiegen, um dann erst wieder nachzugehen! Erstmal an der Seitenlinie beobachten würde ich sagen, wer noch nicht investiert ist. Wer bereits drin ist, sollte seinen SL nachziehen. Aber natürlich alles meine persönliche Meinung und keine Kaufs- oder Verkaufsempfehlung.

Habs dem Chali heute morgen schon geschrieben:

Nachdem STEM gestern bei 1,78 USD(- 13,71 %) geschlossen hatte, war ich heute morgen auf ein Blutbad in meinem Depot gefasst.

Jedoch - nichts da! Das Bid stand sowohl in STU als auch in FRA festgemauert bei 1,68 bis 1,695 Euro.

Umrechnung 1,78 USD in Euro = 1,447!!! Schwein gehabt!

D.h. der gestrige Schlusskurs war in D überhaupt nicht eingepreist!

Hat jemand eine Erklärung dafür? Vorbörslich geht´s nun 25 % up.

Ich habe gerade in usa gekauft. super news. super chart

hoffe ihr seid noch dabei,es könnte sich langfristig lohnen ! Werde bald mit einer grösseren Posi einsteigen ....

MFG
Chali

Ja ich bleibe dabei. Die story ist einfach super. Heute auch gute Nachrichten bei bio firma:ECYT

David G. Birch, Ph.D., Chief Scientific and Executive Officer of the RFSW and Director of the Rose-Silverthorne Retinal Degenerations Laboratory and principal investigator of the study, added, "We are excited to be working with StemCells on this ground breaking clinical trial. There currently are no effective treatments for dry AMD, which is the most common form of the disease, and there is a clear need to explore novel therapeutic approaches."

In February 2012, the Company published preclinical data that demonstrated HuCNS-SC cells protect host photoreceptors and preserve vision in the Royal College of Surgeons (RCS) rat, a well-established animal model of retinal disease which has been used extensively to evaluate potential cell therapies. Moreover, the number of cone photoreceptors, which are responsible for central vision, remained constant over an extended period, consistent with the sustained visual acuity and light sensitivity observed in the study. In humans, degeneration of the cone photoreceptors accounts for the unique pattern of vision loss in dry AMD. The data was published in the international peer-reviewed European Journal of Neuroscience.

About Age-Related Macular Degeneration

Age-related macular degeneration refers to a loss of photoreceptors (rods and cones) from the macula, the central part of the retina. AMD is a degenerative retinal disease that typically strikes adults in their 50s or early 60s, and progresses painlessly, gradually destroying central vision. According to the RFSW website, there are approximately 1.75 million Americans age 40 years and older with some form of age-related macular degeneration, and the disease continues to be the number one cause of irreversible vision loss among senior citizens in the United States with more than seven million at risk of developing AMD.

About the Trial

The Phase I/II trial will evaluate the safety and preliminary efficacy of HuCNS-SC cells as a treatment for dry AMD. The trial will be an open-label, dose-escalation study, and is expected to enroll a total of 16 patients. The HuCNS-SC cells will be administered by a single injection into the space beneath the retina in the most affected eye. Patients' vision will be evaluated using both conventional and advanced state-of-the-art methods of ophthalmological assessment. Evaluations will be performed at predetermined intervals over a one-year period to assess safety and signs of visual benefit. Patients will then be followed for an additional four years in a separate observational study. Patients interested in participating in the clinical trial should contact the site at (214) 363-3911.

About HuCNS-SC Cells

StemCells' proprietary product candidate, HuCNS-SC cells, is a highly purified composition of human neural stem cells that are expanded and stored as banks of cells. The Company's preclinical research has shown that HuCNS-SC cells can be directly transplanted in the central nervous system (CNS) with no sign of tumor formation or adverse effects. Because the transplanted HuCNS-SC cells have been shown to engraft and survive long-term, there is the possibility of a durable clinical effect following a single transplantation. StemCells believes that HuCNS-SC cells may have broad therapeutic application for many diseases and disorders of the CNS, and to date has demonstrated human safety data from completed and ongoing clinical studies.

About The Retina Foundation of the Southwest

The Retina Foundation of the Southwest is an independent, non-profit research organization located in Dallas, Texas. The Foundation has grown into one of the leading independent vision research centers in the United States, with a staff dedicated to finding the causes, treatments and potential cures for blinding eye diseases. Along the way, the Foundation has made a life changing difference in the lives of patients who suffer from retina related diseases. Patients are referred by ophthalmologists from around the world, and because the center is funded by philanthropic and federal grants, patient services are entirely free. The Foundation is a volunteer-driven organization dedicated to making a difference in people's lives by improving their vision -- no matter what their age or financial status. Scientists and clinicians at the Foundation use the power of modern technology to understand the intricacy of retinal function and conduct studies of hereditary and acquired blinding retinal disorders, including retinitis pigmentosa and age-related macular degeneration. Other studies address eye disorders affecting the sight of infants and children, including hereditary eye diseases, cataracts, prematurity and the consequences of eye muscle imbalance. Further information about the RFSW is available at www.retinafoundation.org.

About StemCells, Inc.

StemCells, Inc. is engaged in the research, development, and commercialization of cell-based therapeutics and tools for use in stem cell-based research and drug discovery. The Company's lead therapeutic product candidate, HuCNS-SC(R) cells (purified human neural stem cells), is currently in development as a potential treatment for a broad range of central nervous system disorders. In March 2012, the Company reported results from a Phase I clinical trial in Pelizaeus-Merzbacher disease (PMD), a fatal myelination disorder in children. The trial results showed preliminary evidence of progressive and durable donor-derived myelination in all four patients transplanted with HuCNS-SC cells. The Company is conducting a Phase I/II clinical trial in chronic spinal cord injury in Switzerland and recently reported positive interim safety data for the first patient cohort. The Company is also conducting a Phase I/II clinical trial in dry age-related macular degeneration (AMD). In addition, the Company is pursuing preclinical studies of its HuCNS-SC cells in Alzheimer's disease. StemCells also markets stem cell research products, including media and reagents, under the SC Proven(R) brand. Further information about StemCells is available at www.stemcellsinc.com.

The StemCells, Inc. logo is available at www.globenewswire.com/newsroom/prs/?

MFG
Chali

.... wie es bei Sarepta seit einigen monaten abgeht ? Hintergrund sind gute Phase-2 Ergebnisse einer muskelschwund Krankheit. Das Ganze nur mal als Vorgeschmack,wie es in Zukunft bei Stemcells auch laufen könnte,denn wir sind seit Kurzem im dry and wet AMD Bereich .....

StemCell's premise is to use tissue-derived stem cells only in that same organ, i.e., a homologous approach. For example, to use CNS-derived neural stem cells for the treatment of CNS disorders and liver-derived cells for the treatment of liver disorders. These multi-potent, tissue-derived "adult" stem cells are naturally pre-programmed to become the mature functional cells of the organ in which they are found, so they are directly transplantable into the same type of organ. Conversely, embryonic stem (ES) and induced pluripotent stem (IPS) cells have the potential to differentiate into any of the various cell types of the body, and so they would need to be re-programmed or genetically modified in order to reduce the risk of transplanting unwanted cell types.

While StemCells is a cheaper stock selling for $2.04 a share with a market cap of $62.34M, philanthropist investors might be beginning to take notice of this one -- I think deeper due diligence might be in order for StemCells.

MFG
Chali

www.ariva.de/forum/Like-buying-Apple-in-1997-buy-Organovo-today-470965

Chali

NEWARK, Calif., Oct. 10, 2012 (GLOBE NEWSWIRE) -- StemCells, Inc. (STEM) today announced that two papers reporting clinical and preclinical data demonstrating the therapeutic potential of the Company's proprietary HuCNS-SC(R) cells (purified human neural stem cells) for a range of myelination disorders were published in the Oct. 10 edition of Science Translational Medicine, the peer review journal of the American Association for the Advancement of Science (stm.sciencemag.org/).

The paper by Gupta, et al. describes the encouraging results of the Company's Phase I clinical trial in Pelizaeus-Merzbacher disease (PMD), a genetic myelination disorder that afflicts children. In the trial, which was completed in February 2012, four patients were transplanted with the Company's HuCNS-SC cells and all showed preliminary evidence of progressive and durable donor cell-derived myelination. Three of the four patients showed modest gains in their neurological function, which suggests a departure from the natural history of the disease; the fourth patient remained stable. Although clinical benefit cannot be confirmed in a trial without control patients, the small but measureable gains in function at one year may represent signals of a clinical effect to be further investigated in a controlled trial with more patients.

The second of the two papers, by Uchida, et al., summarizes extensive preclinical research which demonstrated that transplantation of the Company's neural stem cells in an animal model of severe myelin deficiency results in new myelin which enhanced the conductivity of nerve impulses. Myelin is the substance that insulates nerve axons, and without sufficient myelination, nerve impulses are not properly transmitted and neurological function is impaired. This preclinical data provided the rationale for the PMD clinical trial and supports the Company's cell therapy approach to other myelination disorders, such as transverse myelitis, certain forms of cerebral palsy, and multiple sclerosis.

"For the first time, we have evidence that transplanted neural stem cells are able to produce new myelin in patients with a severe myelination disease," Nalin Gupta, MD, PhD, associate professor of neurological surgery and pediatrics and chief of pediatric neurological surgery at UCSF Benioff Children's Hospital, and co-principal investigator of the PMD clinical trial. "We also saw modest gains in neurological function, and while these can't necessarily be attributed to the intervention because this was an uncontrolled trial with a small number of patients, it is an important first step which provides hope that HuCNS-SC transplantation may be able to address the fundamental pathology in the brain of PMD patients."

Patients with PMD have a defective gene which leads to insufficient myelin in the brain, which leads to a progressive loss of neurological function and death. In the clinical trial, four patients with connatal PMD, the most severe form of the disease, were enrolled and transplanted with HuCNS-SC cells. The patients were followed for twelve months after transplantation, during which time they underwent intensive neurological assessments and magnetic resonance (MR) imaging at regular intervals. The findings from the trial indicate a favorable safety profile for the HuCNS-SC cells and the transplantation procedure. Analysis of the MR imaging data showed changes consistent with increased myelination in the region of the transplantation, and which progressed over time and persisted after the withdrawal of immunosuppression at nine months. The results support the conclusion of durable cell engraftment and donor-derived myelin in the transplanted patients' brains. The development of new myelin signals is unprecedented in patients with connatal PMD. In addition, clinical assessment revealed small but measureable gains in motor and/or cognitive function in three of the four patients; the fourth patient remained clinically stable. While clinical benefit cannot be confirmed without a controlled study, these clinical outcomes suggest the HuCNS-SC cells may be having a beneficial effect on the patients.

The second paper, whose lead author is Nobuko Uchida, Vice President of Stem Cell Biology at StemCells, Inc., describes research which shows that when HuCNS-SC cells were transplanted into the shiverer mouse, a common model of severe central nervous system (CNS) dysmyelination, the cells formed new, functional myelin in the mice. Sophisticated analytical techniques were used to confirm that changes measured by MR images were in fact derived from new human myelin generated by the transplanted HuCNS-SC cells. MR imaging is routinely used in the diagnosis and clinical characterization of demyelinating diseases such as multiple sclerosis, and these results supported the use of similar techniques to detect and evaluate the degree of myelination in the Phase I PMD trial. Moreover, the new myelin was shown to be functional as conductivity of nerve impulses in the mice was enhanced.

"Demonstration of functional myelin formation in animals showing disease symptoms is significant and opens up the potential to treat patients with a range of severe myelin disorders," said Stephen A. Back, MD, PhD, professor of pediatrics and neurology at Oregon Health & Science University Doernbecher Children's Hospital, and senior author of the preclinical paper.

Stephen Huhn, MD, FACS, FAAP, Vice President and Head of the CNS Program at StemCells, Inc., added, "Having these two papers published concurrently illustrates the direct pathway of how we are translating groundbreaking scientific research to the clinical setting. The data in these papers make a powerful statement about the potential of our HuCNS-SC cells to address not only PMD, but a wide spectrum of myelination disorders. We are actively moving forward with our plans to conduct a controlled Phase II clinical study in PMD and evaluating our next steps with respect to other myelination disorders."

Conference Call

StemCells, Inc. will host a live webcast, today, October 10, at 4:30 p.m. Eastern Time (1:30 p.m. Pacific Time) to discuss the data reported in these papers. Interested parties are invited to view the webcast over the Internet via the link at www.stemcellsinc.com/News-Events/Events.htm. An archived version of the webcast will be available for replay on the Company's website approximately two hours following the conclusion of the live event and will be available for a period of 30 days.

MFG
Chali

NEW YORK (AP) -- Shares of StemCells Inc. jumped Tuesday after the company said it finished treating the first group of patients in a clinical trial of its stem cell therapy.

THE SPARK: StemCells said it has completed treatment for three patients and is now observing their long-term health. All three had suffered a "complete" spinal cord injury at chest level, which means they had no nerve function or feeling below the area that was injured. The company said two of the patients had greater sensory function a year after treatment, and one had recovered to the point that the injury is now considered "incomplete."

StemCells said that as far as it knows, this is the first time a patient has experienced that kind of improvement after treatment with neural stem cells.

The study measured changes in the patients' sensitivity to touch, heat and electrical stimuli. StemCells said one of the patients didn't experience any improvement.

THE BIG PICTURE: The Newark, Calif., company is studying therapies based on purified adult neural stem cells. It had previously reported that two of the three patients had improved six months after they were treated. StemCells is also testing its treatment on patients with complete injuries, and said it hopes those patients will have similar or larger improvements because they still have some nerve function.

Stem cell therapies are still an experimental field, and StemCells is a small company without any approved products.

SHARE ACTION: StemCells shares climbed 38 cents, or 22.8 percent, to $2.02 in afternoon trading. The stock has doubled in value since-mid July, when the company reported positive preclinical data for an experimental Alzheimer's disease therapy.

MFG
Chali

Mr. McGlynn added, "While we need to be cautious when interpreting data from a small, uncontrolled trial, to our knowledge, this is the first time a patient with a complete spinal cord injury has been converted to a patient with an incomplete injury following transplantation of neural stem cells. We are encouraged that the cells appear to convey clinical benefit in such severely injured patients. We are therefore hopeful that we will see similar or greater benefit in AIS B and C patients, who already have partial sensation and motor function below the level of injury which could be further augmented by cell transplantation."

Patients in the study's first cohort all suffered a complete injury to the thoracic (chest-level) spinal cord. In a complete injury, there is no neurological function below the level of injury, and sensory function of all three patients was stable before transplantation of the HuCNS-SC cells. All three patients were transplanted four to nine months after injury with a dose of 20 million cells at the site of injury. The surgery, immunosuppression and the cell transplants have been well tolerated by all the patients. There were no abnormal clinical, electrophysiological or radiological responses to the cells, and all the patients have remained neurologically stable through the first 12 months following transplantation. Positive changes in sensitivity to touch, heat and electrical stimuli were observed in well-defined and consistent thoracic regions in two of the patients, while no changes were observed in the third patient.  Importantly, quantitative tests of specific sensory function, as well as electrophysiological measures of impulse transmission across the site of injury, show an  association  with the clinical examination, providing further objective confirmation of the sensory gains.

About the Spinal Cord Injury Clinical Trial            

The Phase I/II clinical trial of StemCells, Inc.'s HuCNS-SC® purified human adult neural stem cells is designed to assess both safety and preliminary efficacy. Twelve patients with thoracic (chest-level) neurological injuries at the T2-T11 level are planned for enrollment, and their injuries must have occurred within three to twelve months prior to transplantation of the cells. In addition to assessing safety, the trial will assess preliminary efficacy based on defined clinical endpoints, such as changes in sensation, motor function and bowel/bladder function. The Company has dosed the first three patients, all of whom have injuries classified as AIS A, in which there is no neurological function below the injury level. The injuries are classified according to the American Spinal Injury Association Impairment Scale (AIS). The second and third cohorts will be patients classified as AIS B and AIS C, those with less severe injury, in which there is some preservation of sensory or motor function.

All patients will receive HuCNS-SC cells through direct transplantation into the spinal cord and will be temporarily immunosuppressed. Patients will be evaluated regularly in the post-transplant period in order to monitor and assess the safety of the HuCNS-SC cells, the surgery and the immunosuppression, as well as to measure any recovery of neurological function below the injury site. The Company intends to follow the effects of this therapy long-term, and each of the patients will be invited to enroll into a separate four year observational study after completing the Phase I/II study.

The trial is being conducted at Balgrist University Hospital, University of Zurich, a world leading medical center for spinal cord injury and rehabilitation, and is open for enrollment to patients in Europe, Canada and the United States. Enrollment for the second cohort is currently underway, and the first AIS B patient was enrolled and dosed late last year. If you believe you may qualify and are interested in participating in the study, please contact the study nurse either by phone at +41 44 386 39 01 or by email at stemcells.pz@balgrist.ch.

MFG
Chali

AMD afflicts approximately 30 million people worldwide and is the leading cause of vision loss in people over 55 years of age. Approximately 90 percent of AMD patients have the dry form of the disease, for which there are no approved treatments.

About the Clinical Trial

The Phase I/II trial is designed to evaluate the safety and preliminary efficacy of HuCNS-SC cells as a treatment for dry AMD. The trial is an open-label, dose-escalation study, and is expected to enroll a total of 16 patients. The HuCNS-SC cells will be administered by a single injection into the space beneath the retina in the most affected eye. Using both conventional and advanced state-of-the-art methods of ophthalmological assessment, patients will be evaluated at predetermined intervals over a one-year period to assess safety and signs of visual benefit. Patients will then be followed for an additional four years in a separate observational study.

The trial is currently enrolling at the Byers Eye Institute at Stanford in Palo Alto, California, and at the Retina Foundation of the Southwest in Dallas, Texas. Patients interested in participating in the clinical trial should contact the Byers Eye Institute at Stanford at (650) 498-4486 or the Retina Foundation of the Southwest at (214) 363-3911.

A summary of the Company's preclinical data underlying the trial was featured in February 2012 in the peer-reviewed European Journal of Neuroscience (onlinelibrary.wiley.com/doi/10.1111/...2011.07970.x/abstract). The data demonstrated that HuCNS-SC cells protect host photoreceptors and preserve vision in the Royal College of Surgeons (RCS) rat, a well-established animal model of retinal disease that has been used extensively to evaluate potential cellular therapies. Transplantation of HuCNS-SC cells into RCS rats significantly protected photoreceptors from degeneration. Moreover, the number of cone photoreceptors, which are responsible for central vision, remained constant over an extended period, consistent with the sustained visual acuity and light sensitivity observed in the study. In humans, degeneration of the cone photoreceptors accounts for the unique pattern of vision loss in dry AMD.

About HuCNS-SC Cells

StemCells' lead product candidate, HuCNS-SC cells, is a highly purified composition of human neural stem cells that are expanded and stored as banks of cells. The Company's preclinical research has shown that HuCNS-SC cells can be directly transplanted in the central nervous system (CNS) with no sign of tumor formation or adverse effects. Because the transplanted HuCNS-SC cells have been shown to engraft and survive long-term, this suggests the possibility of a durable clinical effect following a single transplantation. StemCells believes that HuCNS-SC cells may have broad therapeutic application for many diseases and disorders of the CNS, and to date has demonstrated human safety data from completed and ongoing clinical studies

MFG
Chali

StemCells, Inc. Announces New Preclinical Data Showing HuCNS-SC(R) Cells Preserve Visual Function by Keeping Photoreceptors Normal and Healthy
Press Release: StemCells, Inc. – Wed, Sep 18, 2013 9:00 AM

NEWARK, Calif., Sept. 18, 2013 (GLOBE NEWSWIRE) -- StemCells, Inc. (STEM) today announced the publication of preclinical data confirming that the Company's proprietary HuCNS-SC cells (purified human neural stem cells) preserve photoreceptor cells and visual function in a widely used model of retinal degeneration. The data show not only that HuCNS-SC cells preserve the number of photoreceptors that would otherwise be lost, but also that the surviving photoreceptors appear healthy and normal, and maintain their synaptic connection to other important cells necessary for visual function. The study was published in Investigative Ophthalmology and Visual Science (IVOS), the journal of the Association for Research in Vision and Ophthalmology, and is available at (www.iovs.org/content/early/recent.) These results are highly relevant to disorders of vision loss, the most notable of which is age-related macular degeneration (AMD), which afflicts approximately 30 million people worldwide.

"This study demonstrates that, at the cellular and sub-cellular level, the surviving photoreceptors have all the components that characterize a healthy and normal photoreceptor, and they have the correct synaptic connections," said Nicolas Cuenca, PhD, Professor in the Department of Physiology, Genetics and Microbiology at the University of Alicante, Spain, and lead author of the paper. "The robust anatomical preservation of the photoreceptors and their synaptic connections most likely underlie the preservation of visual function.

"In addition, this study confirmed our preliminary hypothesis that HuCNS-SC cells phagocytose photoreceptor outer segments. The phagocytic activity of the HuCNS-SC cells restores a function normally performed by retinal pigmented epithelial (RPE) cells."

The Company is currently conducting a Phase I/II clinical trial in the dry form of AMD, the most prevalent form of the disease. The preclinical data underlying this Phase I/II clinical trial was previously published in the European Journal of Neuroscience (onlinelibrary.wiley.com/doi/10.1111/...2011.07970.x/abstract). That data demonstrated that HuCNS-SC cells protect host photoreceptors (both rods and cones) and preserve vision in the Royal College of Surgeons (RCS) rat, a well-established animal model of retinal disease that has been used extensively to evaluate potential cellular therapies.

The Company's Phase I/II clinical trial in dry AMD is currently enrolling patients at the Byers Eye Institute at Stanford in Palo Alto, California, and at the Retina Foundation of the Southwest in Dallas, Texas. The Company recently dosed the first high-dose patient in the trial. To date, a total of five patients have been dosed in the 16-patient trial. Patients interested in participating in the clinical trial should contact the Byers Eye Institute at Stanford at (650) 498-4486 or the Retina Foundation of the Southwest at (214) 363-3911. The Company is working to open additional sites in the United States

MFG
Chali

"The interim data are very encouraging from two separate perspectives. First, the reduction in the rate of geographic atrophy suggests the HuCNS-SC cells are affecting the underlying cause of AMD. Secondly, the data demonstrates there are increases in contrast sensitivity, which is a vital aspect of visual function," said Stephen Huhn, M.D., FACS, FAAP, vice president, CNS clinical research and chief medical officer at StemCells, Inc. "Impacting the progression of GA and enhancing visual function could have a very meaningful impact on the quality of life for AMD patients and the results to date strongly support our plans to initiate a randomized, controlled, Phase II proof-of-concept trial later this year."

"These interim results have exceeded our expectations at this stage of the trial," said David Birch, Ph.D., chief scientific and executive officer of the Retina Foundation of the Southwest in Dallas, Texas. "These results are particularly interesting given that the first cohort of patients had significant visual impairment and baseline GA. The next cohort of patients will have less impairment and we look forward to learning even more as we analyze data from the patients in the second half of the trial."

StemCells, Inc. will host a conference call and webcast to discuss the interim results from the Phase I/II clinical trial of HuCNS-SC cells in dry AMD, after market close today, Thursday, June 19, at 4:30 p.m. Eastern Daylight Time (1:30 p.m. Pacific Daylight Time).

Interested parties are invited to listen to the call over the Internet by accessing the Investors section of the Company's website at www.stemcellsinc.com. Webcast participants should allot extra time before the webcast begins to register and, if necessary, download and install audio software.

Event: Interim Results from the StemCells, Inc. Phase I/II clinical trial in dry AMD

Date: Thursday, June 19, 2014

Time: 4:30 PM EDT (1:30 PM PDT)

Live webcast: www.media-server.com/m/acs/113baab16d15da4dd0c81018d65a272e

An archived version of the webcast will be available for replay on the Company's website beginning approximately two hours following the conclusion of the live call and continuing for a period of 30 days.

About Age-Related Macular Degeneration and Geographic Atrophy

An estimated 10 million people in the United States either have age-related macular degeneration (AMD) or are at substantial risk for receiving the diagnosis, according to the Foundation Fighting Blindness. AMD, a degenerative retinal disease that typically strikes adults in their 50s or early 60s and gradually progresses to destroy central vision, is the leading cause of blindness in adults over 55 years of age in the developed world. Age-related macular degeneration refers to a loss of photoreceptors (rods and cones) from the macula, the central part of the retina. Approximately 85-90 percent of AMD cases are the "dry" type of the disease, the advanced form of which is referred to as "geographic atrophy."

About the Trial

The Phase I/II trial evaluates the safety and preliminary efficacy of HuCNS-SC cells as a treatment for dry AMD. Patients with dry AMD had to have evidence of GA to be eligible for inclusion. The investigation is divided into two sequential cohorts. Subjects are enrolled into each cohort based on best-corrected visual acuity (BCVA), as determined by the Electronic Early Treatment Diabetic Retinopathy Study (E-ETDRS) acuity test. Patients with BCVA of less than or equal to 20/400 in the study eye were enrolled in Cohort I. Patients with less severe BCVA of 20/320 to 20/100 in the study eye are being enrolled in Cohort II. Cohort I consists of four subjects who were each transplanted with 200,000 stem cells, followed by four subjects who have each been transplanted with 1 million cells. Cohort II will consist of eight subjects who will undergo transplant with 1 million cells. The HuCNS-SC cells are administered by a single injection into the space behind the retina in the most affected eye. Patients' vision is being evaluated using both conventional and advanced state-of-the-art methods of ophthalmological assessment. Evaluations are being performed at predetermined intervals over a one-year period to assess safety and signs of vision improvement. Patients will be followed for an additional four years in a separate observational study.

The trial enrolled at five locations:

   Retina Foundation of the Southwest, Dallas, Texas
   Byers Eye Institute at Stanford, Stanford Hospital and Clinics, Palo Alto, CA
   New York Eye and Ear Infirmary, New York, NY
   Retina Research Institute of Texas, Abilene, TX
   Retina-Vitreous Associates Medical Group, Los Angeles, California

More information about the StemCells Dry Age Related Macular Degeneration program can be found on the Company website at: www.stemcellsinc.com/Therapeutic-Programs/...nal-Disorders.htm

Additional information about the clinical trial is available at: www.stemcellsinc.com/Therapeutic-Programs/Clinical-Trials.htm and at the U.S. National Institutes of Health website at: www.clinicaltrials.gov/ct2/show/...temcells+inc+amd&rank=1

About HuCNS-SC Cells

StemCells, Inc. has demonstrated human safety data from completed and ongoing clinical studies of its proprietary HuCNS-SC cells. StemCells clinicians and scientists believe that HuCNS-SC cells may have broad therapeutic application for many diseases and disorders of the central nervous system (CNS). Because the transplanted HuCNS-SC cells have been shown to engraft and survive long-term, there is the possibility of a durable clinical effect following a single transplantation. The Company's preclinical research established that HuCNS-SC cells can be directly transplanted in the CNS with no sign of tumor formation or adverse effects. The HuCNS-SC platform technology is a highly purified composition of human neural stem cells that are expanded and stored as banks of cells.

About StemCells, Inc.

StemCells, Inc. is engaged in the research, development and commercialization of cell-based therapeutics and tools for use in stem cell-based research and drug discovery. The Company's platform technology, HuCNS-SC® cells (purified human neural stem cells), is currently in clinical development as a potential treatment for a broad range of central nervous system disorders. The Company is conducting a Phase I/II clinical trial in chronic spinal cord injury in Switzerland, Canada and the United States, and has reported positive interim data for the first eight patients. The Company is also conducting a Phase I/II clinical trial in dry age-related macular degeneration (AMD) in the United States. In a Phase I clinical trial in Pelizaeus-Merzbacher disease (PMD), a fatal myelination disorder in children, the Company has shown preliminary evidence of progressive and durable donor-derived myelination in all four patients transplanted with HuCNS-SC cells. In addition, the Company is pursuing preclinical studies in Alzheimer's disease, with support from the California Institute for Regenerative Medicine (CIRM). StemCells also markets stem cell research products, including media and reagents, under the SC Proven® brand. Further information about StemCells is available at www.stemcellsinc.com.

Apart from statements of historical fact, the text of this press release constitutes forward-looking statements within the meaning of the Securities Act of 1933, as amended, and the Securities Exchange Act of 1934, as amended, and is subject to the safe harbors created therein. These statements include, but are not limited to, statements regarding the prospect of the Company's HuCNS-SC cells to preserve vision; the prospect and timing of patient enrollment in the Company's clinical trial in dry AMD; and the future business operations of the Company. These forward-looking statements speak only as of the date of this news release. The Company does not undertake to update any of these forward-looking statements to reflect events or circumstances that occur after the date hereof. Such statements reflect management's current views and are based on certain assumptions that may or may not ultimately prove valid. The Company's actual results may vary materially from those contemplated in such forward-looking statements due to risks and uncertainties to which the Company is subject, including the fact that additional trials will be required to demonstrate the safety and efficacy of the Company's HuCNS-SC cells for the treatment of any disease or disorder; uncertainty as to whether the FDA or other applicable regulatory agencies or review boards will permit the Company to continue clinical testing in AMD; uncertainties regarding the timing and duration of any clinical trials; uncertainties regarding the Company's ability to recruit the patients required to conduct its clinical trials or to obtain meaningful results; uncertainties regarding the Company's ability to obtain the increased capital resources needed to continue its current and planned research and development operations; uncertainty as to whether HuCNS-SC cells and any products that may be generated in the future in the Company's cell-based programs will prove safe and clinically effective and not cause tumors or other adverse side effects; and other factors that are described under the heading "Risk Factors" in the Company's Annual Report on Form 10-K for the year ended December 31, 2013, and in its subsequent reports on Forms 10-Q and 8-K.

Was siehst/glaubst Du für ein Kursziele.

Eigentlich doch bei akuteller MK doch weit > 10$.

War mal investiert und habe leider schon vor einem Jahr verkauft mit nem kleinen Minus.

Überleg, jetzt einzusteigen, hab mich aber nicht mehr zu stark damit beschäftigt.

Wie ist dein EK und Deine Meinung?

Gruss, Eco1

Wie man am Langfrist-Chart erkennen kann, kriecht Stemcells wirklich am Boden. Die Krisenzeit (Rezession) hat viele Aktien stark gebeutelt. Eine technische Korrektur ohne weitere News wird meiner Meinung kommen, da die Investoren sich wieder eindecken werden. Bei Bio-Aktien geht es um viel Phantsie und Hoffnung. Weiß jemand, welche Präparate Stemcells hat und in welchen Phasen die sich aktuell befinden?

charts.comdirect.de/charts/...mp;WITH_EARNINGS=1&SHOWHL=1" style="max-width:560px" alt="">AAlle Angaben ohne Gewähr!

Habe mal selber gestöbert! Interessant!

Stemcells Now Covered by Brinson Patrick (STEM)
July 2nd, 2014 - 0 comments - Filed Under - by Mark Dietrich
Share on StockTwits


Stemcells logoBrinson Patrick started coverage on shares of Stemcells (NASDAQ:STEM) in a research note issued on Wednesday, TheFlyOnTheWall.com reports. The firm set an “outperform” rating and a $7.00 price target on the stock. Brinson Patrick’s price objective would suggest a potential upside of 250.00% from the company’s current price.

STEM has been the subject of a number of other recent research reports. Analysts at Maxim Group raised their price target on shares of Stemcells from $2.50 to $5.00 in a research note on Friday, June 20th. They now have a “buy” rating on the stock. Separately, analysts at Chardan Capital reiterated a “positive” rating on shares of Stemcells in a research note on Tuesday, June 17th.

Shares of Stemcells (NASDAQ:STEM) opened at 2.00 on Wednesday. Stemcells has a 52 week low of $1.15 and a 52 week high of $2.34. The stock’s 50-day moving average is $1.57 and its 200-day moving average is $1.43. The company’s market cap is $111.0 million.

Stemcells (NASDAQ:STEM) last posted its quarterly earnings results on Wednesday, May 14th. The company reported ($0.14) earnings per share (EPS) for the quarter, missing the consensus estimate of ($0.12) by $0.02. The company had revenue of $0.34 million for the quarter, compared to the consensus estimate of $0.24 million. During the same quarter in the previous year, the company posted ($0.17) earnings per share. On average, analysts predict that Stemcells will post $-0.60 earnings per share for the current fiscal year.

StemCells, Inc (NASDAQ:STEM) is engaged in the research, development, and commercialization of stem cell therapeutics and related enabling technologies for academia and industry.

sorry, aber ich hab keine ahnung, wohin das geht, aber andere s.o. wissen da besser bescheid...umsatz legt stark zu, vielversprechende pipline...also ich bin long und hoffe auf viel mehr...
gruss

www.oanda.com/lang/de/currency/converter/

Mich wundert es, das die Leute Aktien wie Geron, Viropharma, Stemcells heute kaum hier noch Aufmerksamkeit bekommen in den Threads...? Hatte deswegen auch in USA gekauft.  Zum Glück sehen es die Amis anders...Auf alte Zeiten und fettes Plus im Depot!!:-) Viel Glück den investierten!

charts.comdirect.de/charts/...mp;WITH_EARNINGS=1&SHOWHL=1" style="max-width:560px" alt="">

habe noch US85857B1008 im Depot, hat aber hiermit nichts zu tun? oder etwa doch??

Börse: Nasdaq
Aktuell: 2,33 USD
      Zeit§02.07.14 18:31
Diff. Vortag: +16,50%
Tages-Vol.: 22,35 Mio.
Gehandelte Stück: 10,47 Mio.
Geld: 2,33
Brief: 2,34
Zeit: 02.07.14 18:31

Was ist da los, bisher kein Handel? Weiß da jemand mehr?


Kursdaten
     Börse    Nasdaq§
   Aktuell§2,34 USD
      Zeit§03.07.14 19:00
Diff. Vortag +2,18%
Tages-Vol.§12,25 Mio.
Gehandelte Stück 5,35 Mio.
      Geld      2,27§
     Brief      3,47§
      Zeit§03.07.14 23:00
    Spread§34,58%
Geld Stk. 3.000
Brief Stk. 3.000

Bin auch drauf reingefallen, ;)

kann mir vorstellen, das da bald etwas mehr schub rein kommt...lg

schön. Montag vielleicht.  

hier... keiner mehr dabei???

11/20/14 StemCells, Inc. Investor and Analyst Event
Thursday, November 20, 2014 12:00p.m. ET

globenewswire.com/news-release/2014/12/18/...-Cord-Injury.html

Zock könnte mal wieder drin sein, der Kurs ist ja ganz schön runter seit dem letzten Hype.  

sehe ich auch so! da sind schnell wieder 50% drinne!

Bezieht sich das nicht auf ein anderes Unternehmen? OTC Aktie?

ich lass es löschen!;p

Panischer Abverkauf nach- + vorbörslich: --24% $ 0,64 (09:15) EastTime USA

StemCells, Inc. Announces Proposed Public Offering of Common Stock and Warrants

www.nasdaq.com/press-release/...ck-and-warrants-20150423-01430

Hier dürfte heute das Allzeittief von $0,59 (04.06.2012) getestet werden.

charts.comdirect.de/charts/...mp;WITH_EARNINGS=1&SHOWHL=1" style="max-width:560px" alt="">

Ich frage lieber nicht und sage, daß das heutecharttechnisch interessant ist

habe das gekauft. Mal sehen was wird

Übersetzt mit Google:

StemCells, Inc. kündigt geplante Börsengang von Stammaktien und Optionsscheine
Von Globenewswire, 23. April 2015, 04.14.00 EDT
Vote up

NEWARK, Kalifornien, 23. April 2015 (GLOBE NEWSWIRE) - StemCells, Inc. (Nasdaq: STEM). Gab heute bekannt, dass sie beabsichtigt, anbieten und verkaufen Stammaktien und Warrants, vorbehaltlich Markt- und anderen Bedingungen, in einem garantierten öffentlichen Zeichnungsangebot . Die Aktien und Optionsscheine werden unter wirksamen Shelf Registration Statement des Unternehmens zuvor mit der Securities and Exchange Commission (SEC) eingereicht angeboten. StemCells beabsichtigt, den Nettoemissionserlös für allgemeine Unternehmenszwecke, einschließlich Working Capital, Investitionen und Forschung und Entwicklung zu verwenden.

Maxim Group LLC wird als Sole Book läuft Manager für das Angebot zu handeln.

Die Wertpapiere werden mit Hilfe eines Prospektnachtrags und des zugehörigen Prospekts angeboten, einen Teil der effektiven Registrierungserklärung bilden, kann eine Kopie davon erhalten werden kann, wenn verfügbar, auf der Website der SEC unter http: //www.sec. gov. Elektronische Kopien des vorläufigen Prospekts kann auch von Maxim Group LLC, 405 Lexington Avenue, 2nd Floor, New York, NY 10174 erhalten werden kann, bei 212-895-3500.

Diese Pressemitteilung stellt weder ein Angebot zum Verkauf noch eine Aufforderung zur Abgabe eines Angebots zum Kauf von Wertpapieren dar, diese, noch soll ein Verkauf dieser Wertpapiere in einer Rechtsordnung, in der ein solches Angebot, Verkaufswerbung oder Verkauf ungesetzlich wäre vor der Registrierung oder Qualifizierung nach den Wertpapiergesetzen dieser Gerichtsbarkeit.

Über StemCells, Inc.

StemCells, Inc. wird gegenwärtig einge klinischen Entwicklung des Plattformtechnologie HuCNS-SC® (gereinigte menschliche neurale Stammzellen) als eine potenzielle Behandlung von Störungen des zentralen Nervensystems (ZNS). Interimsdaten aus der Phase des Unternehmens I / II-Studie in der Thoraxrückenmarksverletzungen (SCI) zeigt messbare Gewinne, die mehrere Sinnesmodalitäten und Segmente, einschließlich der Umsetzung von 2 von 7 Patienten in der Studie mit komplettem Verletzungen (AIS A) Umwandlung in eingeschrieben unvollständigen Verletzungen (AIS B), nach der Transplantation. Einschreibung hat vor kurzem in klinischen Phase-II-Studie des Unternehmens in Hals SCI begonnen. StemCells, Inc. hat sich auch ausgefüllte Anmelde und Behandlung in der Phase-I / II-Studie in geographischer Atrophie der altersbedingten Makuladegeneration (GA-AMD), der schwersten Form von trockener AMD, die die Hauptursache für Erblindung in der ist ältere Menschen. Basierend auf vorläufigen Ergebnisse für Patienten mit 12 Monate Daten meldete das Unternehmen eine 70-prozentige Reduktion der Rate der Krankheitsprogression im Vergleich zu der Kontrolle (unbehandelt) Auge und ein 65 Prozent Verringerung der Rate der Krankheitsprogression im Vergleich zu den erwarteten Natur Krankheitsgeschichte. In einer klinischen Phase I-Studie bei Pelizaeus-Merzbacher-Krankheit (PMD), eine tödliche Myelinisierung Unordnung in Kindern, zeigte das Unternehmen erste Hinweise der fortschreitenden und dauerhaften Spender abgeleiteten Myelinisierung in allen vier Patienten mit HuCNS-SC Zellen transplantiert.

Quelle:
Weiterlesen: www.nasdaq.com/press-release/...s-20150423-01430#ixzz3YXj5apRg

Vorsichtige Gemüter kaufen erst bei 0,59$, Erbsenzähler *frühestens* bei 0,54$, so sie denn zum Zuge kommen. Wie Du siehst, ich bin immer ein wenig vorlaut?!

e

Wertpapiername STEM CELL INNOVAT. DL-,01
ISIN / WKN US85857B1008 / A0JDMC

Hat das was mit dieser Aktie zu tun?

aber stemcells ist sehr interessant, gibst ja schon länger am markt...charts.comdirect.de/charts/...mp;WITH_EARNINGS=1&SHOWHL=1" style="max-width:560px" alt="">

Quelle: Comdirect

07.07.11

Reverse Split

10:1

Nein, sind unterschiedliche Unternehmen meiner Meinung!

auf derz. Kursniveau.

könnte auch noch ein Resplitt folgen. Siehe Chart 2011!  

auch heute wieder.
www.nasdaq.com/de/symbol/stem/real-time

im Sinne des TE, günstig wie nie
:-)

e

ist halt eine Teilmenge von interessant.

In diesem Sinne

und sehen STEM als +500% Aktie
Ende Juni soll eine FDA Entscheidung anliegen.
In der Pipeline ist auch einiges.
www.stemcellsinc.com/Clinical-Programs/Overview
Dürfte also im Vorfeld anziehen, daher auch schon das steigende Volumen und der Anstieg die letzten Wochen.

und an der MA50 exakt abgeprallt.
Chart und Unternehmen schauen vielversprechend aus, auch die Branche ist zur Zeit im Fokus. Hohe Umsätze Gestern. Charttechnisch wäre erstmal Luft bis knapp 1 USD
Hürde ist erstmal die MA50(0,77) darüber frei Fahrt bis 0,92-1,00

als wäre der boden immer noch nicht gefunden, geht ja wieder in die andere Richtung

ist hier noch jemand drin? oder jetzt erst recht?

war so klar nachdem die ganzen Aktien magazine das empfehlen, das es down geht...denke es kann noch wesentlich tiefer gehen

das ist nurnoch roulette

Stammzellaktien scheinen wieder in Mode zu kommen. Mal schauen, ob Steamcell auch ein Übernahmeziel wird...

€ 0,735 zu e 0,798

www.boerse-frankfurt.de/de/aktien/...inc+dl+01+ag+US85857R2040

premarket +62% und schon jetzt gutes volumen  

hoffe dass wir an knio anknüpfen können

offensichtlich

www.nasdaq.com/de/symbol/stem/real-time

ist noch jemand drin hier?

nur das übliche bei stemcells: dilution,dilution,dilution ! Das wird noch jahrelang so weiter gehen,weil Stemcells nix in Phase 3 hat,deshlöab hab ich in der Vetrgangenheit auch nicht gekauft,und werde auch in den nächsten 5 Jahren nicht kaufwn,zwecklos !

Noch deutlich günstiger als Stemcells ist Cesca Therapeutics (KOOL),die hatten grad einen Reverse split und eine Phase 3 zu critcal limb ischemia steht an,interessant,würde ich kaufen ....

MFG
Chali

ich bin mit einem kleinen Zock mal eingestiegen..
www.nasdaq.com/de/symbol/stem/real-time

Warum steigt die Aktie 500%?  

nach News, denke ich.

www.smarteranalyst.com/2016/08/16/...nnounce-strategic-merger/

Wünsche ich mir bei verastem auch :)  

www.nasdaq.com/de/symbol/stem/after-hours

www.nasdaq.com/de/symbol/stem/real-time

So wie es aussieht ist das so eine Art Manteldeal.
Microbot wird zur Tochter von Stemcells, um sich die Arbeit Kosten für den Börsengang zu sparen!
Wieviel die Kiste wert ist, hab ich allerdings noch nirgends gefunden.

Könnte wieder über die 2,50 klettern, wenn sie die 2,10 erstmal überwunden hat.

und keine Kommentare hier? hmmm
Bis zum 28. soll der Merger über die Bühne gehen.....

Schaue nach längerer Zeit wieder rein und meine schöne Stemcells ist "weg"...
Gab es einen Reversesplit?  

29.11.16 Reverse Split 9:1
09.05.16 Reverse Split 12:1

ih.advfn.com/p.php?pid=nmona&article=73922931

ih.advfn.com/p.php?pid=nmona&article=73924997

Jemand was hier abgeht.

Ich vermute das es eine Fusion gab, Stemcells wurde scheinbar von Microbot Medical Inc. übernommen bzw. mit denen verschmelzt, der Aktienchart von Stemcells ist geblieben. Was mich etwas abschreckt, sind die beiden Reversesplits in einem Jahr und trotzdem hat man wieder 34,81 Mio. Aktien am Markt (Quelle: Comdirect). Die Daten bei Ariva scheinen nicht mehr aktuell zu sein oder?  Laut Ariva: Aktienanzahl:  1,81 Mio. (Stand: 05.12.16). Vermutlich wieder verwässert, so etwas kotzt einen echt an an der Nasdaq, die geben den Aktienkursen gar keine Zeit mehr, normal sich zu entwickeln?